Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

New β-Lactamase Inhibitors in the Clinic

(2016) Krisztina M. Papp-Wallace et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Time for a change: addressing R&D and commercialization challenges for antibacterials

(2015) D. J. Payne et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli

(2011) M. Tärnberg et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus  -lactamase-producing Enterobacteriaceae

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhibitor Resistance in the KPC-2  -Lactamase, a Preeminent Property of This Class A  -Lactamase

(2009) K. M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Orthodox and unorthodox clavulanate combinations against extended-spectrum β-lactamase producers

(2008) D.M. Livermore et al.   CLINICAL MICROBIOLOGY AND INFECTION